The blockade of immune checkpoints in cancer immunotherapy

Cited by (1,121)

Items 301–400 of 1,121

1. Emerging therapeutic opportunities for integrin inhibitors
   Robert J. Slack, Simon J. F. Macdonald, James A. Roper, Gisli R. Jenkins, Richard J. D. Hatley · 2021 · Nature Reviews Drug Discovery
2. Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
   Kishton, Rigel J., Sukumar, Madhusudhanan, Restifo, Nicholas P. · 2017 · Cell Metabolism
3. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
   Lee‐Shing Chang, Romualdo Barroso‐Sousa, Sara M. Tolaney, Frank Stephen Hodi, Ursula B. Kaiser, Le Min · 2018 · Endocrine Reviews
4. TIGIT predominantly regulates the immune response via regulatory T cells
   Sema Kurtuluş, Kaori Sakuishi, Shin Foong Ngiow, Nicole Joller, Dewar J. Tan, Michele W.L. Teng, Mark John Smyth, Vijay Kumar Kuchroo, Ana Carrizosa Anderson · 2015 · Journal of Clinical Investigation · Retracted
5. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer
   Xiaoxian Li, Jing Liang Yang, Limin Peng, Ayşegül A. Şahin, Lei Huo, Kevin C. Ward, Ruth M O'Regan, Mylin Ann Torres, Jane Lowe Meisel · 2016 · Breast Cancer Research and Treatment
6. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
   Martin Reck, Alexander Valerievich Luft, Aleksandra Szczęsna, Libor Havel, Sang-We Kim, Wallace Akerley, Maria Catherine Pietanza, Yi-Long Lung Cancer Wu, Christoph Carl Zielinski, Michael Thomas et al. · 2016 · Journal of Clinical Oncology
7. Updates on global epidemiology, risk and prognostic factors of gastric cancer
   Wenjuan Yang, Heping Zhao, Yan Ping Yu, Ji-Han Wang, Lei Guo, Jun-Ye Liu, Jie Pu, Jing Lv · 2023 · World Journal of Gastroenterology
8. Genetic Mechanisms of Immune Evasion in Colorectal Cancer
   Grasso, Catherine S., Giannakis, Marios, Wells, Daniel K., Hamada, Tsuyoshi, Mu, Xinmeng Jasmine, Quist, Michael, Nowak, Jonathan A., Nishihara, Reiko, Qian, Zhi Rong, Inamura, Kentaro et al. · 2018 · Cancer Discovery
9. Clinical update on head and neck cancer: molecular biology and ongoing challenges
   Elham Alsahafi, Katheryn Begg, Ivano Amelio, Nina Raulf, Philippe Lucarelli, Thomas Sauter, Mahvash Tavassoli · 2019 · Cell Death and Disease
10. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer
    Ganesan, Anusha-Preethi, Clarke, James, Wood, Oliver, Garrido-Martin, Eva M, Chee, Serena J, Mellows, Toby, Samaniego-Castruita, Daniela, Singh, Divya, Seumois, Grégory, Alzetani, Aiman et al. · 2017 · Nature Immunology
11. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
    Jason R. Westin, Fuliang Chu, Min Zhang, Luis Fayad, Larry W. Kwak, Nathan Hale Fowler, Jorge Enrique Romaguera, Fredrick B. Hagemeister, Michelle A. Fanale, Felipe Samaniego et al. · 2013 · The Lancet Oncology
12. Genetics and biology of pancreatic ductal adenocarcinoma
    Ying, Haoqiang, Dey, Prasenjit, Yao, Wantong, Kimmelman, Alec C., Draetta, Giulio F., Maitra, Anirban, DePinho, Ronald A. · 2016 · Genes & Development
13. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
    Adel Naimi, Rebar N. Mohammed, Ahmed Raji, Supat Chupradit, Alexei Valerievich Yumashev, Wanich Suksatan, Mohammed Nader Shalaby, Lakshmi Prasanth Thangavelu, Siavash Kamrava, Navid Shomali et al. · 2022 · Cell Communication and Signaling
14. Stem cell programs in cancer initiation, progression, and therapy resistance
    Huang, Tianzhi, Song, Xiao, Xu, Dandan, Tiek, Deanna, Goenka, Anshika, Wu, Bingli, Sastry, Namratha, Hu, Bo, Cheng, Shi-Yuan · 2020 · Theranostics
15. A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
    Xiaojun Liu, Raghuveer Ranganathan, Shuguang Jiang, Chongyun Fang, Jing Sun, Soyeon Kim, Kheng Newick, Albert Lo, Carl H. June, Yangbing Zhao et al. · 2016 · Cancer Research
16. Manganese Oxide Nanomaterials: Synthesis, Properties, and Theranostic Applications
    Binbin Ding, Pan Zheng, Ping’an Ma, Jun Lin · 2020 · Advanced Materials
17. Novel patterns of response under immunotherapy
    Édith Borcoman, Yada Kanjanapan, Stéphane Champiat, Shotaro Kato, Vincent Servois, Razelle Kurzrock, Sanjay Goel, Philippe Lucien Bedard, Christophe Le Tourneau · 2019 · Annals of Oncology
18. Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses
    Nikhil S. Joshi, Elliot H. Akama‐Garren, Yisi Lu, Da-Yae Lee, Gregory P. Chang, Amy Li, Michel J.P. DuPage, Tuomas Tammela, Natanya R. Kerper, Anna F. Farago et al. · 2015 · Immunity
19. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
    D. Ross Camidge, Robert Charles Doebele, Keith M. Kerr · 2019 · Nature Reviews Clinical Oncology
20. Breast Cancer Treatments: Updates and New Challenges
    Anna Burguin, Caroline Diorio, Francine Durocher · 2021 · Journal of Personalized Medicine
21. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
    Stephen Joseph Bagley, Shawn Kothari, Charu Aggarwal, Joshua Michael Bauml, Evan W. Alley, Tracey L. Evans, John A. Kosteva, Christine Agnes Ciunci, Peter Edward Gabriel, Jeffrey C. Thompson et al. · 2017 · Lung Cancer
22. Theranostic Fluorescent Probes
    Amit Kumar Sharma, Peter Verwilst, Mingle Li, Dandan Ma, Nem Singh, Jiyoung Yoo, Yujin Kim, Ying Yang, Jinghui Zhu, Haiqiao Huang et al. · 2024 · Chemical Reviews
23. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
    Patrick Alexander Ott, Yung‐Jue Bang, Dominique Berton-Rigaud, Elena Élez, Michael Jon Pishvaian, Hope S. Rugo, Igor J. Puzanov, Janice M. Mehnert, Kyaw Lwin Aung, Juanita Suzanne Lopez et al. · 2017 · Journal of Clinical Oncology
24. PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
    Fatemeh Karimi Dermani, Pouria Samadi, Golebagh Rahmani, Alisa Khodadadi Kohlan, Rezvan Najafi · 2018 · Journal of Cellular Physiology
25. Chlorin-Based Nanoscale Metal–Organic Framework Systemically Rejects Colorectal Cancers via Synergistic Photodynamic Therapy and Checkpoint Blockade Immunotherapy
    Kuangda Lu, Chunbai He, Nining Guo, Christina Chan, Kaiyuan Ni, Ralph R. Weichselbaum, Wenbin Lin · 2016 · Journal of the American Chemical Society
26. Tumor Microenvironment‐Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade
    Fangyuan Zhou, Bing Feng, Haijun Yu, Dangge Wang, Tingting Wang, Yuting Ma, Siling Wang, Yaping Li · 2019 · Advanced Materials
27. Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
    Gettinger, Scott, Rizvi, Naiyer A., Chow, Laura Q., Borghaei, Hossein, Brahmer, Julie, Ready, Neal, Gerber, David E., Shepherd, Frances A., Antonia, Scott, Goldman, Jonathan W. et al. · 2016 · Journal of Clinical Oncology
28. Epigenetic control of CD8+ T cell differentiation
    Amanda N. Henning, Rahul Roychoudhuri, Nicholas P. Restifo · 2018 · Nature reviews. Immunology
29. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
    Capone, Mariaelena, Giannarelli, Diana, Mallardo, Domenico, Madonna, Gabriele, Festino, Lucia, Grimaldi, Antonio Maria, Vanella, Vito, Simeone, Ester, Paone, Miriam, Palmieri, Giuseppe et al. · 2018 · Journal for ImmunoTherapy of Cancer
30. Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients
    Niels Halama, Inka Zoernig, Anna Berthel, Christoph Kahlert, Fee Klupp, Meggy Suarez‐Carmona, Thomas Sütterlin, Karsten Brand, Juergen Krauss, Felix Lasitschka et al. · 2016 · Cancer Cell
31. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
    Aurélie Durgeau, Yasemin Virk, Stéphanie Corgnac, Fathia Mami‐Chouaib · 2018 · Frontiers in Immunology
32. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
    Yan Lan, Dong Zhang, Chunxiao Xu, Kenneth W. Hance, Bo Marelli, Jin Qi, Huakui Yu, Guozhong Qin, Aroop Sircar, Vivian M. Hernández et al. · 2018 · Science Translational Medicine
33. Combined local immunostimulatory radioisotope therapy and systemic immune checkpoint blockade imparts potent antitumour responses
    Yu Chao, Ligeng Xu, Chao Liang, Liangzhu Feng, Jun Xu, Ziliang Dong, Longlong Tian, Xuan Yi, Kai Yang, Zhuang Liu · 2018 · Nature Biomedical Engineering
34. Analyses of repeated failures in cancer therapy for solid tumors: Poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs
    Maeda, Hiroshi, Khatami, Mahin · 2018 · Clinical and Translational Medicine
35. Update on Fundamental Mechanisms of Thyroid Cancer
    Alessandro Prete, Patricia Borges de Souza, Simona Censi, Marina Muzza, Nicole Nucci, Marialuisa Sponziello · 2020 · Frontiers in Endocrinology
36. Engineering CAR-T cells: Design concepts
    Shivani Srivastava, Stanley R. Riddell · 2015 · Trends in Immunology
37. VISTA Regulates the Development of Protective Antitumor Immunity
    Isabelle Le Mercier, Wenna Chen, Janet Louise Lines, Maria Day, Jiannan Li, Petra A. Sergent, Randolph J. Noelle, Li Lily Wang · 2014 · Cancer Research
38. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
    Michael Orth, Philipp Metzger, Sabine Gerum, Julia V. Mayerle, Günter Schneider, Claus Belka, Maximilian Schnurr, Kirsten Lauber · 2019 · Radiation Oncology
39. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
    Evan W. Alley, Juanita Suzanne Lopez, Armando Santoro, Anne Morosky, Sanatan Saraf, Bilal Piperdi, Emilie M.J. van Brummelen · 2017 · The Lancet Oncology
40. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer
    Patrick Hall Lizotte, Amy M. Wen, Mee Rie Sheen, J. Fields, Pakdee Rojanasopondist, Nicole F. Steinmetz, Steven Fiering · 2015 · Nature Nanotechnology
41. Big opportunities for small molecules in immuno-oncology
    Jerry L. Adams, James F . Smothers, Roopa Srinivasan, Axel Hoos · 2015 · Nature Reviews Drug Discovery
42. Cancer epigenetics: Moving forward
    Angela Nebbioso, Francesco Paolo Tambaro, Carmela Dell’Aversana, Lucia Altucci · 2018 · PLoS Genetics
43. Blocking PD-L1–PD-1 improves senescence surveillance and ageing phenotypes
    Teh‐Wei Wang, Yoshikazu Johmura, Narumi Suzuki, Satotaka Omori, Toshiro Migita, Kiyoshi Yamaguchi, Seira Hatakeyama, Satoshi Yamazaki, Eigo Shimizu, Seiya Imoto et al. · 2022 · Nature
44. Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts
    Jérôme Paggetti, Franziska Haderk, Martina Seiffert, Bassam Janji, Ute Distler, Wim Ammerlaan, Yeoun Jin Kim, Julien Adam, Peter Lichter, Éric Solary et al. · 2015 · Blood
45. Immune Checkpoint Inhibitors: Basics and Challenges
    Bin Li, Ho Lam Chan, Pingping Chen · 2017 · Current Medicinal Chemistry
46. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
    Pengfei Wang, Yang Chen, Siying Song, Tingjian Wang, Wenjun Ji, Shouwei Li, Ning Liu, Changxiang Yan · 2017 · Frontiers in Pharmacology
47. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
    Panagiotis Sarantis, Evangelos Koustas, Adriana Papadimitropoulou, Athanasios G. Papavassiliou, Michalis V. Karamouzis · 2020 · World Journal of Gastrointestinal Oncology
48. Classification of current anticancer immunotherapies
    Lorenzo Galluzzi, Erika Vacchelli, José Manuel Bravo‐San Pedro, Aitziber Buqué, Laura Senovilla, Elisa Elena Baracco, Norma Bloy, Francesca Castoldi, Jean‐Pierre Abastado, Patrizia Agostinis et al. · 2014 · Oncotarget
49. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis
    Bernhard Mlecnik, Gabriela Bindea, Amos Kirilovsky, Helen K. Angell, Anna C. Obenauf, Marie Tosolini, SE Church, Pauline Maby, Angela Vasaturo, Mihaela Angelova et al. · 2016 · Science Translational Medicine
50. Differential fates of biomolecules delivered to target cells via extracellular vesicles
    Masamitsu Kanada, Michael H. Bachmann, Jonathan W. Hardy, Daniel Omar Frimannson, Laura L. Bronsart, Andrew Wang, Matthew D. Sylvester, Tobi L. Schmidt, Roger L. Kaspar, Manish J. Butte et al. · 2015 · Proceedings of the National Academy of Sciences
51. M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors
    Yeon Woong Choo, Mikyung Kang, Han Young Kim, Jin Han, Seokyung Kang, Ju‐Ro Lee, Gun‐Jae Jeong, Sung Pil Kwon, Seuk Young Song, Seokhyeong Go et al. · 2018 · ACS Nano
52. Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
    Rituparna Das, Rakesh Verma, Mario Sznol, Chandra Sekhar Boddupalli, Scott N. Gettinger, Harriet M. Kluger, Margaret K. Callahan, Jedd D. Wolchok, Ruth Halaban, Madhav V. Dhodapkar et al. · 2014 · The Journal of Immunology
53. Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
    Jennifer E. Kim, Mira A. Patel, Antonella Mangraviti, Eileen S. Kim, Debebe Theodros, Esteban Velarde, Ann Liu, Eric W. Sankey, Ada J Tam, Haiying Xu et al. · 2016 · Clinical Cancer Research
54. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells
    Pamela M. Odorizzi, Kristen E. Pauken, Michael Paley, Arlene H. Sharpe, E. John Wherry · 2015 · The Journal of Experimental Medicine
55. Mechanisms regulating PD-L1 expression on tumor and immune cells
    Shuming Chen, George Austin Crabill, Theresa S. Pritchard, Tracee L. McMiller, Ping Yen Wei, Drew M. Pardoll, Fan Pan, Suzanne Louise Topalian · 2019 · Journal for ImmunoTherapy of Cancer
56. Acquired resistance to immunotherapy and future challenges
    Nicholas P. Restifo, Mark John Smyth, Alexandra Snyder · 2016 · Nature reviews. Cancer
57. TGF-β1 – A truly transforming growth factor in fibrosis and immunity
    Monika Lodyga, Boris Hinz · 2019 · Seminars in Cell and Developmental Biology
58. Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
    Huiying Han, Atul D. Jain, Mihai Ioan Truica, Javier Izquierdo-Ferrer, Jonathan Forrest Anker, Barbara Lysy, Vinay Sagar, Yi Luan, Zachary Rockow Chalmers, Kenji Unno et al. · 2019 · Cancer Cell
59. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
    Shaveta Vinayak, Sara M. Tolaney, Lee Steven Schwartzberg, Monica M Mita, Georgia Anne-Lee McCann, Antoinette R. Tan, Andrea E. Wahner-Hendrickson, Andres Forero, Carey K. Anders, Gerburg M. Wulf et al. · 2019 · JAMA Oncology
60. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer
    Weijun Wan, Xiang Ao, Quan Chen, Yu Pu Yang, Luoquan Ao, Wei Xing, Wei Guo, Xiaofeng Wu, Chengxiu Pu, Xueting Hu et al. · 2022 · Molecular Cancer
61. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma
    Winograd, Rafael, Byrne, Katelyn T., Evans, Rebecca A., Odorizzi, Pamela M., Meyer, Anders R.L., Bajor, David L., Clendenin, Cynthia, Stanger, Ben Z., Furth, Emma E., Wherry, E. John et al. · 2015 · Cancer Immunology Research
62. Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
    Bertrand Allard, Sandra Pommey, Mark John Smyth, John Stagg · 2013 · Clinical Cancer Research
63. Photodynamic Therapy Mediated by Nontoxic Core–Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer
    Xiaopin Duan, Christina Chan, Nining Guo, Wenbo Han, Ralph R. Weichselbaum, Wenbin Lin · 2016 · Journal of the American Chemical Society
64. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
    Tuba Nur Gide, James S. Wilmott, Richard A. Scolyer, Georgina Venetia Long · 2017 · Clinical Cancer Research
65. Colorectal Cancer Immunotherapy: Options and Strategies
    Nor Adzimah Johdi, NUR FAZILAH SUKOR · 2020 · Frontiers in Immunology
66. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
    Paolino, Magdalena, Choidas, Axel, Wallner, Stephanie, Pranjic, Blanka, Uribesalgo, Iris, Loeser, Stefanie, Jamieson, Amanda M., Langdon, Wallace Y., Ikeda, Fumiyo, Fededa, Juan Pablo et al. · 2014 · Nature
67. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
    Kohei Shitara, Jaffer A. Ajani, Markus Hermann Moehler, Marcelo Garrido S, Carlos Gallardo, Lin Shen, Kensei Yamaguchi, Lucjan Stanislaw Wyrwicz, Tomasz Skoczylas, Arinilda Silva Campos Bragagnoli et al. · 2022 · Nature
68. Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma
    Prat, Aleix, Navarro, Alejandro, Paré, Laia, Reguart, Noemí, Galván, Patricia, Pascual, Tomás, Martínez, Alex, Nuciforo, Paolo, Comerma, Laura, Alos, Llucia et al. · 2017 · Cancer Research
69. Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
    Mengyu Chang, Zhiyao Hou, Man Wang, Chunxia Li, Jun Lin · 2020 · Advanced Materials
70. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
    Ranee Mehra, Tanguy Y. Seiwert, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Ann Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang et al. · 2018 · British Journal of Cancer
71. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
    Luisa Carbognin, Sara Pilotto, Michèle Milella, Vanja Vaccaro, Matteo Brunelli, Anna Caliò, Federica Cuppone, Isabella Sperduti, Diana Giannarelli, Marco Chilosi et al. · 2015 · PLoS ONE
72. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
    Sanlorenzo, Martina, Vujic, Igor, Daud, Adil, Algazi, Alain, Gubens, Matthew, Luna, Sara Alcántara, Lin, Kevin, Quaglino, Pietro, Rappersberger, Klemens, Ortiz-Urda, Susana · 2015 · JAMA Dermatology
73. Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma
    Chiu, David Kung-Chun, Tse, Aki Pui-Wah, Xu, Iris Ming-Jing, Di Cui, Jane, Lai, Robin Kit-Ho, Li, Lynna Lan, Koh, Hui-Yu, Tsang, Felice Ho-Ching, Wei, Larry Lai, Wong, Chun-Ming et al. · 2017 · Nature Communications
74. Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses
    Abhishek Dinkarnath Garg, Patrizia Agostinis · 2017 · Immunological Reviews
75. Therapeutic targeting of trained immunity
    Willem J. M. Mulder, Jordi Ochando, Leo A. B. Joosten, Zahi Adel Fayad, Mihai Gheorghe Netea · 2019 · Nature Reviews Drug Discovery
76. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
    Liu, Li, Mayes, Patrick A., Eastman, Stephen, Shi, Hong, Yadavilli, Sapna, Zhang, Tianqian, Yang, Jingsong, Seestaller-Wehr, Laura, Zhang, Shu-Yun, Hopson, Chris et al. · 2015 · Clinical Cancer Research
77. PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy
    Salmaninejad, Arash, Valilou, Saeed Farajzadeh, Shabgah, Arezoo Gowhari, Aslani, Saeed, Alimardani, Malihe, Pasdar, Alireza, Sahebkar, Amirhossein · 2019 · Journal of Cellular Physiology
78. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
    Tina Gruosso, Mathieu Gigoux, Venkata SK. Manem, Nicholas Bertos, Dongmei Zuo, Irina Perlitch, Sadiq M.I. Saleh, Hong Zhao, Margarita Souleimanova, Radia Marie Johnson et al. · 2019 · Journal of Clinical Investigation
79. Survivin: a unique target for tumor therapy
    Himani Garg, Prerna Suri, Jagdish Chandra Gupta, Gursaran P. Talwar, Shweta Dubey · 2016 · Cancer Cell International
80. Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
    Noha Abdel‐Wahab, Mohsin Shah, Maria Eugenia Suarez-Almazor · 2016 · PLoS ONE
81. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy
    Jordan A. Krall, Ferenc Reinhardt, Oblaise A. Mercury, Diwakar Ram Pattabiraman, Mary W. Brooks, Michael Lawrence Dougan, Arthur W. Lambert, Brian Bierie, Hidde L. Ploegh, Stephanie K. Dougan et al. · 2018 · Science Translational Medicine
82. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
    Kipp Weiskopf, Nadine S. Jahchan, Peter John Schnorr, Sandra Cristea, Aaron M. Ring, Roy L. Maute, Anne Kathrin Volkmer, Jens-Peter Volkmer, Jie Liu, Jing Shan Lim et al. · 2016 · Journal of Clinical Investigation
83. Programming CAR-T cells to kill cancer
    Louai Labanieh, Robbie G. Majzner, Crystal Lee Mackall · 2018 · Nature Biomedical Engineering
84. The immunology of renal cell carcinoma
    Claudia Marcela Diaz-Montero, Brian I. Rini, James Harold Finke · 2020 · Nature Reviews Nephrology
85. Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
    Keiichi Ota, Koichi Azuma, Akihiko Kawahara, Satoshi Hattori, Eiji Iwama, Junko Tanizaki, Taishi Harada, Koichiro Matsumoto, Koichi Takayama, Shinzo Takamori et al. · 2015 · Clinical Cancer Research
86. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
    Jung-Mao Hsu, Weiya Xia, Yi-Hsin Hsu, Li-Chuan Chan, Wen-Hsuan Yu, Jong‐Ho Cha, Chun‐Te Chen, Hsin-Wei Liao, Chu‐Wei Kuo, Kay‐Hooi Khoo et al. · 2018 · Nature Communications
87. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
    Daniel G. Coit, John A. Thompson, Mark R. Albertini, Christopher Andrew Barker, William Edgar Carson, Carlo M. Contreras, Gregory A. Daniels, Dominick J. DiMaio, Ryan Courtney Fields, Martin D. Fleming et al. · 2019 · Journal of the National Comprehensive Cancer Network
88. Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy
    Chao Liang, Ligeng Xu, Guosheng Song, Zhuang Liu · 2016 · Chemical Society Reviews
89. B lymphocytes and cancer: a love-hate relationship
    Yuen, Grace J., Demissie, Ezana, Pillai, Shiv · 2016 · Trends in cancer
90. The emerging role of epigenetic therapeutics in immuno-oncology
    Topper, Michael J., Vaz, Michelle, Marrone, Kristen A., Brahmer, Julie R., Baylin, Stephen B. · 2020 · Nature Reviews Clinical Oncology
91. The ever-expanding role of HIF in tumour and stromal biology
    Edward L. LaGory, Amato J. Giaccia · 2016 · Nature Cell Biology
92. Precision glycocalyx editing as a strategy for cancer immunotherapy
    Han Xiao, Elliot C. Woods, Petar Vukojicic, Carolyn Ruth Bertozzi · 2016 · Proceedings of the National Academy of Sciences
93. Immune Microenvironment in Glioblastoma Subtypes
    Zhihong Chen, Dolores Hambardzumyan · 2018 · Frontiers in Immunology
94. Myeloid-Derived Suppressor Cells Enhance Stemness of Cancer Cells by Inducing MicroRNA101 and Suppressing the Corepressor CtBP2
    Tracy Xiao Cui, Ilona Kryczek, Lili Zhao, Ende Zhao, Rork D. Kuick, Michael H. Roh, Linda Vatan, Wojciech Szeliga, Yujun Mao, Dafydd G. Thomas et al. · 2013 · Immunity
95. 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
    Messina, Jane L., Fenstermacher, David A., Eschrich, Steven, Qu, Xiaotao, Berglund, Anders E., Lloyd, Mark C., Schell, Michael J., Sondak, Vernon K., Weber, Jeffrey S., Mulé, James J. · 2012 · Scientific Reports
96. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease
    Baruch, Kuti, Deczkowska, Aleksandra, Rosenzweig, Neta, Tsitsou-Kampeli, Afroditi, Sharif, Alaa Mohammad, Matcovitch-Natan, Orit, Kertser, Alexander, David, Eyal, Amit, Ido, Schwartz, Michal · 2016 · Nature Medicine
97. Tumor Microenvironment and Differential Responses to Therapy
    Hirata, Eishu, Sahai, Erik · 2017 · Cold Spring Harbor Perspectives in Medicine
98. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
    Michele Maio, Arnaud Scherpereel, Luana Calabrò, Joachim G.J.V. Aerts, S. Cedrés, Alessandra Bearz, Kristiaan Nackaerts, Dean Anthony Fennell, Dariusz Mirosław Kowalski, Anne S. Tsao et al. · 2017 · The Lancet Oncology
99. Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer
    Kurt Alex Schalper, Jason Robert Brown, Daniel Carvajal‐Hausdorf, Joseph Francis McLaughlin, Vamsidhar Velcheti, Konstantinos Nikolaos Syrigos, Roy S. Herbst, David L. Rimm · 2015 · JNCI Journal of the National Cancer Institute
100. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
     Belum, V.R., Benhuri, B., Postow, M.A., Hellmann, M.D., Lesokhin, A.M., Segal, N.H., Motzer, R.J., Wu, S., Busam, K.J., Wolchok, J.D. et al. · 2016 · European Journal of Cancer